In a cohort of 86 patients with MMR-deficient tumours, including four patients with CCA, immune checkpoint blockade with the anti-PDL1 monoclonal antibody pembrolizumab resulted in a complete response in one of the patients with CCA and stabilization of disease in the other three232. This evidence concerns the gene CD274 and cholangiocarcinoma.